Fig. 1

Analysis of mutations targeted in MMR-proficient and MMR-deficient CT26 after injection in immunocompromised and immunocompetent mice. A Experimental workflow employed for the analysis of mutations (SNVs and indels) in WGS data of CT26 Mlh1^+/+ and Mlh1^-/- samples. Briefly, each CT26 clone was inoculated into NOD-SCID (immunocompromised) and BALB/c (immunocompetent) mice 150 days after genome editing. CT26 MMR-proficient and MMR-deficient tumors underwent WGS at the time of injection and after excision from the mice when tumors reached 1200 mm³ of volume in NOD-SCID mice. In the case of BALB/c mice, the tumors were excised when they reached volumes of 1100 mm³ and 800 mm³ for Mlh1^+/+ and Mlh1^-/- tumors, respectively. Delta between log fold changes evaluated after injection in immunocompromised and immunocompetent mice in CT26 Mlh1^+/+ (B) and CT26 Mlh1^-/- (C). Log fold changes analysis of gained and lost alterations was calculated from CT26 Mlh1^+/+ and Mlh1^-/- pre-injection data, respectively. The alterations were grouped in regions and normalized per Mb before log fold change calculation